Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune Neutralisation and Coagulation Factor X-dependent Cell Interaction and
Adenoviruses are mostly considered self-limiting pathogens associated with respiratory, gastrointestinal and ocular infections; however, in immunocompromised subjects disseminated Ad infection can occur with life-threatening consequences. Many human Ads are capable of binding to coagulation factor X (FX). Following intravenous administration in animal models, FX binds directly to the major Ad capsid protein, the hexon, which subsequently results in virus accumulation in the liver. FX coating Ad5 also acts to shield against immune neutralisation via natural IgM antibodies and the classical complement system. Here we show that FX protection is not a conserved mechanism amongst Ads and identify the Ad5 hexon hypervariable regions (HVR) as the capsid proteins targeted by this host defense pathway. Furthermore, we show that genetic inclusion of Ad5 HVRs onto a native non-FX binder Ad26 to be sufficient to confer sensitivity to immune attack in vitro and in vivo. Using intravenous administration, we determine the significance of FX binding to the Ad5-derived HVRs with respect to defending the virus from neutralisation whilst mediating virus tropism. Our study gives new insight into the role of the viral HVRs and of FX at the interface between virus and host defense mechanisms.
Vyšlo v časopise:
Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune Neutralisation and Coagulation Factor X-dependent Cell Interaction and. PLoS Pathog 11(2): e32767. doi:10.1371/journal.ppat.1004673
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1004673
Souhrn
Adenoviruses are mostly considered self-limiting pathogens associated with respiratory, gastrointestinal and ocular infections; however, in immunocompromised subjects disseminated Ad infection can occur with life-threatening consequences. Many human Ads are capable of binding to coagulation factor X (FX). Following intravenous administration in animal models, FX binds directly to the major Ad capsid protein, the hexon, which subsequently results in virus accumulation in the liver. FX coating Ad5 also acts to shield against immune neutralisation via natural IgM antibodies and the classical complement system. Here we show that FX protection is not a conserved mechanism amongst Ads and identify the Ad5 hexon hypervariable regions (HVR) as the capsid proteins targeted by this host defense pathway. Furthermore, we show that genetic inclusion of Ad5 HVRs onto a native non-FX binder Ad26 to be sufficient to confer sensitivity to immune attack in vitro and in vivo. Using intravenous administration, we determine the significance of FX binding to the Ad5-derived HVRs with respect to defending the virus from neutralisation whilst mediating virus tropism. Our study gives new insight into the role of the viral HVRs and of FX at the interface between virus and host defense mechanisms.
Zdroje
1. Chuang YY, Chiu CH, Wong KS, Huang JG, Huang YC, et al. (2003) Severe adenovirus infection in children. J Microbiol Immunol Infect 36: 37–40. 12741731
2. Echavarría M (2008) Adenoviruses in Immunocompromised Hosts. Clinical Microbiology Reviews 21: 704–715. doi: 10.1128/CMR.00052-07 18854488
3. Straussberg R, Harel L, Levy Y, Amir J (2001) A Syndrome of Transient Encephalopathy Associated With Adenovirus Infection. Pediatrics 107: e69. 11331719
4. Abzug MJ, Levin MJ (1991) Neonatal adenovirus infection: four patients and review of the literature. Pediatrics 87: 890–896. 2034495
5. Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, et al. (2003) Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102: 1114–1120. 12702513
6. Echavarria M, Forman M, van Tol MJD, Vossen JM, Charache P, et al. (2001) Prediction of severe disseminated adenovirus infection by serum PCR. The Lancet 358: 384–385. 11502321
7. Munoz RE, Piedra PA, Demmler GJ (1998) Disseminated Adenovirus Disease in Immunocompromised and Immunocompetent Children. Clinical Infectious Diseases 27: 1194–1200. 9827268
8. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, et al. (2002) Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100: 1619–1627. 12176880
9. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al. (1997) Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5. Science 275: 1320–1323. 9036860
10. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR (1993) Integrins ±v²3 and ±v²5 promote adenovirus internalization but not virus attachment. 73: 309–319. 8477447
11. Greber UF, Suomalainen M, Stidwill RP, Boucke K, Ebersold MW, et al. (1997) The role of the nuclear pore complex in adenovirus DNA entry. 5998–6007 p.
12. Suomalainen M, Nakano MY, Keller S, Boucke K, Stidwill RP, et al. (1999) Microtubule-dependent Plus- and Minus End–directed Motilities Are Competing Processes for Nuclear Targeting of Adenovirus. The Journal of Cell Biology 144: 657–672. 10037788
13. Robinson CM, Singh G, Lee JY, Dehghan S, Rajaiya J, et al. (2013) Molecular evolution of human adenoviruses. Sci Rep 3. doi: 10.1038/srep03544 24384914
14. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. Journal of Virology 81: 4654–4663. 17329340
15. Lieber A, He C-Y, Meuse L, Schowalter D, Kirillova I, et al. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of virology 71: 8798–8807. 9343240
16. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, et al. (2009) Virus Binding to a Plasma Membrane Receptor Triggers Interleukin-1α-Mediated Proinflammatory Macrophage Response In Vivo. Immunity 31: 110–121. doi: 10.1016/j.immuni.2009.04.015 19576795
17. Cotter MJ, Zaiss AK, Muruve DA (2005) Neutrophils Interact with Adenovirus Vectors via Fc Receptors and Complement Receptor 1. Journal of Virology 79: 14622–14631. 16282462
18. Tian J, Xu Z, Smith JS, Hofherr SE, Barry MA, et al. (2009) Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo. Journal of Virology 83: 5648–5658. doi: 10.1128/JVI.00082-09 19321608
19. Xu Z, Qiu Q, Tian J, Smith JS, Conenello GM, et al. (2013) Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nature medicine 19: 452–457. doi: 10.1038/nm.3107 23524342
20. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D (2007) Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109: 2832–2839. 17148587
21. Stone D, Liu Y, Shayakhmetov D, Li Z-Y, Ni S, et al. (2007) Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the Liver. Journal of Virology 81: 4866–4871. 17301138
22. Carlisle RC, Di Y, Cerny AM, Sonnen AF-P, Sim RB, et al. (2009) Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. 1909–1918 p. doi: 10.1182/blood-2008-09-178459 19131551
23. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, et al. (2006) Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery. Mol Ther 14: 118–128. 16580883
24. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397–409. doi: 10.1016/j.cell.2008.01.016 18267072
25. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, et al. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proceedings of the National Academy of Sciences 105: 5483–5488. doi: 10.1073/pnas.0711757105 18391209
26. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, et al. (2008) Substitution of Hexon Hypervariable Region 5 of Adenovirus Serotype 5 Abrogates Blood Factor Binding and Limits Gene Transfer to Liver. Mol Ther 16: 1474–1480. doi: 10.1038/mt.2008.132 18560416
27. Bertheau P, Parquet N, Ferchal F, Gluckman E, Brocheriou C (1996) Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 17: 295–298. 8640184
28. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW (1999) Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow Transplant 23: 1209–1211. 10382964
29. Johnson PR, Yin JA, Morris DJ, Desai M, Cinkotai KI, et al. (1990) Fulminant hepatic necrosis caused by adenovirus type 5 following bone marrow transplantation. Bone Marrow Transplant 5: 345–347. 2161693
30. Alba R, Bradshaw AC, Mestre-Frances N, Verdier JM, Henaff D, et al. (2012) Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Ther 19: 109–113. doi: 10.1038/gt.2011.87 21677690
31. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108: 2554–2561. 16788098
32. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood.
33. Bradshaw AC, Parker AL, Duffy MR, Coughlan L, van Rooijen N, et al. (2010) Requirements for Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X. PLoS Pathog 6: e1001142. doi: 10.1371/journal.ppat.1001142 20949078
34. Duffy MR, Bradshaw AC, Parker AL, McVey JH, Baker AH (2011) A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes. Journal of Virology 85: 10914–10919. doi: 10.1128/JVI.05382-11 21849463
35. Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. 2656–2664 p.
36. Irons EE, Flatt JW, Doronin K, Fox TL, Acchione M, et al. (2013) Coagulation Factor Binding Orientation and Dimerization May Influence Infectivity of Adenovirus-Coagulation Factor Complexes. Journal of Virology 87: 9610–9619. doi: 10.1128/JVI.01070-13 23804638
37. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, et al. (2012) Coagulation factor X activates innate immunity to human species C adenovirus. Science 338: 795–798. doi: 10.1126/science.1226625 23019612
38. Kojouharova M, Reid K, Gadjeva M (2010) New insights into the molecular mechanisms of classical complement activation. Molecular Immunology 47: 2154–2160. doi: 10.1016/j.molimm.2010.05.011 20542571
39. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, et al. (2002) The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. European Journal of Cancer 38: 1917–1926. 12204675
40. Khare R, Reddy VS, Nemerow GR, Barry MA (2012) Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors. Journal of Virology 86: 2293–2301. doi: 10.1128/JVI.05760-11 22156515
41. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, et al. (2012) Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys. Journal of Virology 86: 10862–10865. doi: 10.1128/JVI.00928-12 22811531
42. Chen H, Xiang ZQ, Li Y, Kurupati RK, Jia B, et al. (2010) Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae. Journal of Virology 84: 10522–10532. doi: 10.1128/JVI.00450-10 20686035
43. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, et al. (2012) First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). Journal of Infectious Diseases.
44. Vollmers HP, Brändlein S (2006) Natural IgM antibodies: The orphaned molecules in immune surveillance. Advanced Drug Delivery Reviews 58: 755–765. 16820243
45. Klimovich VB (2011) IgM and its receptors: Structural and functional aspects. Biochemistry (Moscow) 76: 534–549. doi: 10.1134/S0006297911050038 21639833
46. Uchida K (2014) Natural antibodies as a sensor of electronegative damage-associated molecular patterns (DAMPs). Free Radical Biology and Medicine 72: 156–161. doi: 10.1016/j.freeradbiomed.2014.03.016 24657731
47. Chikazawa M, Otaki N, Shibata T, Miyashita H, Kawai Y, et al. (2013) Multispecificity of Immunoglobulin M Antibodies Raised against Advanced Glycation End Products: INVOLVEMENT OF ELECTRONEGATIVE POTENTIAL OF ANTIGENS. Journal of Biological Chemistry 288: 13204–13214. doi: 10.1074/jbc.M113.452177 23543734
48. Perreau M, Guerin M-C, Drouet C, Kremer EJ (2007) Interactions Between Human Plasma Components and A Xenogenic Adenovirus Vector: Reduced Immunogenicity During Gene Transfer. Mol Ther 15: 1998–2007. 17712332
49. Sumida SM, Truitt DM, Lemckert AAC, Vogels R, Custers JHHV, et al. (2005) Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein. The Journal of Immunology 174: 7179–7185. 15905562
50. Roberts DM, Nanda A, Havenga MJE, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239–243. 16625206
51. Parker AL, Waddington SN, Buckley SMK, Custers J, Havenga MJE, et al. (2009) Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer. Journal of Virology 83: 479–483. doi: 10.1128/JVI.01878-08 18945780
52. Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, et al. (2009) The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog 5: e1000277. doi: 10.1371/journal.ppat.1000277 19119424
53. Nicol CG, Graham D, Miller WH, White SJ, Smith TAG, et al. (2004) Effect of Adenovirus Serotype 5 Fiber and Penton Modifications on in vivo Tropism in Rats. Mol Ther 10: 344–354. 15294181
54. Bordigoni P, Carret A-S, Venard V, Witz F, Le Faou A (2001) Treatment of Adenovirus Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases 32: 1290–1297. 11303263
55. Lenaerts L, Naesens L (2006) Antiviral therapy for adenovirus infections. Antiviral Research 71: 172–180. 16698093
56. Duffy MR, Parker AL, Kalkman ER, White K, Kovalskyy D, et al. (2013) Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release 170: 132–140. doi: 10.1016/j.jconrel.2013.05.007 23702233
57. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, et al. (2003) Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity. Journal of Virology 77: 8263–8271. 12857895
58. Greig JA, Buckley SMK, Waddington SN, Parker AL, Bhella D, et al. (2009) Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. Mol Ther 17: 1683–1691. doi: 10.1038/mt.2009.152 19603000
59. Alba R, Baker A, Nicklin S (2012) Vector Systems for Prenatal Gene Therapy: Principles of Adenovirus Design and Production. In: Coutelle C, Waddington SN, editors. Prenatal Gene Therapy: Humana Press. pp. 55–84.
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2015 Číslo 2
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Control of Murine Cytomegalovirus Infection by γδ T Cells
- ATPaseTb2, a Unique Membrane-bound FoF1-ATPase Component, Is Essential in Bloodstream and Dyskinetoplastic Trypanosomes
- Rational Development of an Attenuated Recombinant Cyprinid Herpesvirus 3 Vaccine Using Prokaryotic Mutagenesis and In Vivo Bioluminescent Imaging
- Direct Binding of Retromer to Human Papillomavirus Type 16 Minor Capsid Protein L2 Mediates Endosome Exit during Viral Infection